BWX Technologies heads into the final stretch before its August 4 earnings report with options traders still notably more defensive than the lending market warrants.
The options story has not resolved since last week's note flagged it. The put/call ratio hit 0.54 on June 16 — up from roughly 0.31 where it spent most of the prior four weeks — and now sits at a z-score of 4.3 standard deviations above its 20-day mean. That's the highest reading of the past year bar a brief spike on April 30. For context, the PCR was running between 0.27 and 0.32 for virtually every session from May through early June before this shift. The move is concentrated in a single session, which is worth noting: Tuesday's PCR dropped straight back to 0.31, suggesting this is not a steady accumulation of downside hedges but a discrete, large put position entered on Monday.
The lending picture continues to describe a completely different kind of market. Short interest has fallen another 5% on the week, and is now down 13% over the past month, reaching 2.6% of the free float. Availability remains extraordinary — roughly 22 shares available to borrow for every one lent out, nearly three times the 52-week tightest reading. Cost to borrow eased to 0.46%, down 8% on the week and barely above the floor. Nothing in the borrow market points to meaningful bearish conviction; if anything, shorts have been covering steadily since mid-May's brief spike to 3.7% of float.
The Street remains broadly constructive, though the data is now about three weeks old. Deutsche Bank upgraded to Buy and raised its target to $255 in mid-May, a call that stands out as the most directionally significant recent action. The consensus sits at Buy across eight analysts, with a mean target near $238 — about 21% above the current price of $196.93. Wells Fargo's April initiation at Underweight with a $200 target is the lone bear on the board. The bull case centres on nuclear tailwinds: naval propulsion contracts, the PCG medical isotope acquisition, and rising commercial nuclear demand. Bears point to government concentration risk and the slow-scaling industrial fabrication business. Valuation is not cheap: the stock trades at roughly 40x trailing earnings and close to 28x EV/EBITDA, which keeps Truist and Seaport on the sidelines despite raising targets.
Peer performance this week adds a layer of colour. CW — the most highly correlated peer — gained 4.2%, nearly matching BWXT's own 4.2% weekly advance. AIR did better at 8.2%, and KRMN surged 6.9%. HII, the most direct comparison in naval defense, gained less than half a percent. BWXT's week was solid but not standout relative to the peer group, which broadly benefited from the same aerospace and defense tailwinds.
Insider activity remains a mild background negative. CEO Rex Geveden sold roughly $2 million in stock on May 12 across multiple tranches, and the CFO added two further sales in early May. These are low-significance transactions by ORTEX scoring and may reflect routine plan-driven selling, but the net 90-day insider flow of $9.6 million in shares sold is a consistent directional signal that insiders have not been adding at current prices. The next read on whether that changes comes when the August 4 earnings window opens.
What to watch: whether the Monday PCR spike proves to be a one-session artefact — the Tuesday snap-back to 0.31 suggests it might — or whether put demand builds again before the August print is the key question the options tape will answer over the coming weeks.
See the live data behind this article on ORTEX.
Open BWXT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
